Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 09 - 07 save search
ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
Published: 2021-09-07 (Crawled : 20:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.32%
H: 0.69%
C: -0.27%
ESPR | $2.115 1.2% 1.18% 5.4M
|
Health Technology
|
| O: 0.25%
H: 1.17%
C: -3.25%
treatment cholesterol
Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
Published: 2021-09-07 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.2%
H: 0.59%
C: -1.08%
disease treatment eye eye disease trial
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
Published: 2021-09-07 (Crawled : 14:00) - biospace.com/
CADL | $6.03 2.03% 1.99% 670K
|
|
| O: 1.84%
H: 28.19%
C: 20.0%
media treatment risk prostate cancer cancer phase 3 trial enroll
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
Published: 2021-09-07 (Crawled : 13:15) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 1.23%
H: 1.51%
C: -2.39%
new drug disease treatment fda oxbryta children drug fda acceptance
Envista Announces Intended Sale Of KaVo Treatment Unit & Instrument Business To Planmeca
Published: 2021-09-07 (Crawled : 13:00) - prnewswire.com
NVST | $20.28 0.3% 0.0% 1.2M
|
Health Technology
|
| O: -1.23%
H: 0.0%
C: -1.01%
treatment
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Published: 2021-09-07 (Crawled : 12:15) - biospace.com/
RDY | $70.92 -0.8% 0.0% 150K
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: -0.48%
CTXR | $0.7199 -6.18% -6.58% 880K
|
Health Technology
|
| O: 3.37%
H: 5.93%
C: -1.4%
treatment immunotherapy therapy cancer license phase 3 t-cell e7777
MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults
Published: 2021-09-07 (Crawled : 12:15) - globenewswire.com
RARE F | $44.26 -1.88% -1.92% 670K
|
Health Technology
|
| O: 1.8%
H: 1.99%
C: -0.35%
canada approval media treatment injection approval
Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 1.99%
H: 1.12%
C: -0.91%
treatment test cancer
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.85%
H: 0.37%
C: -0.8%
treatment china therapy keytruda
RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors
Published: 2021-09-07 (Crawled : 10:00) - prnewswire.com
RNXT | $1.26 5.0% 4.76% 3.5K
|
|
| O: 41.19%
H: 0.09%
C: -10.68%
treatment solid tumors liver clearance designation
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
Published: 2021-09-07 (Crawled : 09:00) - biospace.com/
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: 1.96%
H: 2.88%
C: 0.68%
treatment acquisition opioid chronic pain
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Published: 2021-09-07 (Crawled : 07:00) - globenewswire.com
TLSA | News | $0.781 0.77% 0.77% 330K
|
Health Technology
|
| O: 4.69%
H: 1.99%
C: -1.0%
treatment foralumab cancer antibody license car-t
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.